Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]) |
| |
Institution: | 1. Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand;2. Brigham and Women''s Hospital, Heart & Vascular Center, and Harvard Medical School, Boston, Massachusetts;3. Beth Israel Hospital, Boston, Massachusetts;4. University of Giessen and Kerckhoff Heart Center, Bad Nauheim, Germany;6. Department of Medicine, Stanford University School of Medicine, Stanford, California;5. Scripps Clinic and Scripps Translational Science Institute, La Jolla, California;7. Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France;11. Université Paris-Diderot, Sorbonne-Paris Cité, Paris, France;12. Royal Brompton Hospital, London, United Kingdom;8. Columbia University Medical Center and The Cardiovascular Research Foundation, New York, New York;10. Interventional Cardiology, A.O. Fatebenefratelli, Bastioni di Porta Nuova, Milan, Italy;9. Cardiology PC, Birmingham, Alabama |
| |
Abstract: | ObjectivesThe aim of this study was to examine the efficacy and bleeding outcomes of cangrelor in patients in the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention PCI]) who underwent percutaneous coronary intervention with bivalirudin.BackgroundCangrelor is a potent intravenous P2Y12 inhibitor with rapid onset and offset. In the CHAMPION PHOENIX, cangrelor compared with clopidogrel significantly reduced 48-h ischemic events including stent thrombosis, without increasing major bleeding. Bivalirudin has demonstrated ischemic outcomes similar to those with heparin plus glycoprotein IIb/IIIa inhibition, with reduced bleeding but increased early stent thrombosis.MethodsIn the modified intent-to-treat population, 2,059 patients (18.8%) received bivalirudin, with 1,014 patients in the cangrelor treatment arm and 1,045 in the clopidogrel treatment arm.ResultsAt 48 h, the primary endpoint of death, myocardial infarction, ischemia-driven revascularization, or stent thrombosis was lower with cangrelor versus clopidogrel (48 4.7%] vs. 70 6.7%]; odds ratio OR]: 0.68, p = 0.047). Death was similar in both arms (2 0.2%] vs. 2 0.2%]). Myocardial infarction was reduced by cangrelor (37 3.6%] vs. 59 5.6%]; OR: 0.63, p = 0.03), as was death/myocardial infarction (39 3.8%] vs. 61 5.8%]; OR: 0.65, p = 0.04). Cangrelor was associated with a nonsignificant trend toward less stent thrombosis (7 0.7%] vs. 15 1.4%]; OR: 0.48, p = 0.10), which was evident within 2 h after percutaneous coronary intervention (p = 0.057). GUSTO (Global Use of Strategies to Open Occluded Arteries) severe bleeding was similar in both arms (2 of 1,021 0.2%] vs. 2 of 1,055 0.2%]) as were other bleeding definitions and transfusions. Efficacy and safety results were consistent in patients with stable angina, non–ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction (p for interaction: 0.62 and 0.29).ConclusionsCangrelor may offer an attractive benefit risk profile when used in combination with bivalirudin. |
| |
Keywords: | bivalirudin cangrelor CHAMPION PHOENIX stent thrombosis CI"} {"#name":"keyword" "$":{"id":"kwrd0035"} "$$":[{"#name":"text" "_":"confidence interval GUSTO"} {"#name":"keyword" "$":{"id":"kwrd0045"} "$$":[{"#name":"text" "_":"Global Use of Strategies to Open Occluded Arteries IDR"} {"#name":"keyword" "$":{"id":"kwrd0055"} "$$":[{"#name":"text" "_":"ischemia-driven revascularization MI"} {"#name":"keyword" "$":{"id":"kwrd0065"} "$$":[{"#name":"text" "_":"myocardial infarction mITT"} {"#name":"keyword" "$":{"id":"kwrd0075"} "$$":[{"#name":"text" "_":"modified intention-to-treat NSTE-ACS"} {"#name":"keyword" "$":{"id":"kwrd0085"} "$$":[{"#name":"text" "_":"non–ST-segment elevation acute coronary syndrome OR"} {"#name":"keyword" "$":{"id":"kwrd0095"} "$$":[{"#name":"text" "_":"odds ratio PCI"} {"#name":"keyword" "$":{"id":"kwrd0105"} "$$":[{"#name":"text" "_":"percutaneous coronary intervention STEMI"} {"#name":"keyword" "$":{"id":"kwrd0115"} "$$":[{"#name":"text" "_":"ST-segment elevation myocardial infarction TIMI"} {"#name":"keyword" "$":{"id":"kwrd0125"} "$$":[{"#name":"text" "_":"Thrombolysis In Myocardial Infarction |
本文献已被 ScienceDirect 等数据库收录! |
|